Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Novel venom-based peptides (P13 and its derivative—M6) to maintain self-renewal of human embryonic stem cells by activating FGF and TGFβ signaling pathways

Fig. 5

The expressions of p-Erk1/2 and p-Smad2 in the human ES cells treated with M6 without/with small molecular inhibitors. a The expression of total/phosphorylation Erk1/2 and total/phosphorylation Smad2 when treated with P13 and its mutant M6 without any inhibitor. b The expressions of the TGFβ signaling pathways after being treated with TGFβ receptor inhibitors (LDN-193189, SB431542, and A8301); the concentration of SB431542 was 1.0 and 10 μmol, and the concentration of A8301/LDN-193189 was 0.2 and 1.0 μmol. c The expression of the FGFR pathways after being treated with FGFR receptor inhibitors (AZD4547 and PD173074); the concentration of AZD4547 was 0.2 μmol, and the concentration of PD173074 was 1.0 μmol. d The expressions of the FGF and TGFβ signaling pathways after being treated with the FGFR and TGFβ receptor dual inhibitors (0.2 μmol AZD4547 and 1.0 μmol A8301)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512